Search jobs Parp Inhibitors Market SWOT analysis and Key Business Strategies, Demand & Forecast – 2030
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP).
PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These PARP inhibitors used to treat subset of ovarian cancer. Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data. The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015. PARP inhibitors mainly i
Japan
Dubai
Dubayy
United-arab-emirates
United-states
India
America
Abhishek-budholiya
Asia-pacific
Pfizer
Astrazeneca
World-health-organization
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: CHOICE-01 Phase III Study of Toripalimab at the Interim Analysis Met Pre-Specified Primary Endpoint of Progression-Free Survival at the First-Line Treatment of Advanced NSCLC
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
GuangzhouGuangdongChinaShanghaiUnited-statesSuzhouJiangsuBeijingMarylandSan-franciscoCaliforniaChinese(2)
EQS Group-Ad-hoc: Polyphor AG / Key word(s): Study
Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications
14-Dec-2020 / 07:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
Allschwil, Switzerland, December 14, 2020
Polyphor announces third positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III balixafortide FORTRESS study without modifications
Polyphor AG (SIX: POLN) announced today that the clinical trial independent Data Safety Monitoring Board (DSMB) has completed the third, pre-specified interim analysis, of safety outcomes based on a data cut off of 401 randomized patients in the Phase III pivotal study with balixafortide in HER2 negative, locally recurrent or metastatic breast cancer patients. The DSMB indicated that the Phase III clinical study shou
Allschwil
Switzerland-general
Switzerland
Swiss
Hernan-levett
Mary-ann-chang
Bernhard-schmid
Frank-weber
Group-news-service
Eqs-group
Polyphor-ltd
Swiss-exchange